Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433091/
https://ncbi.nlm.nih.gov/pubmed/22689860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-396853
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak